Pluri (PLUR) Expected to Announce Quarterly Earnings on Thursday

Pluri (NASDAQ:PLUR) is expected to be posting its results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.6550 million for the quarter.

Pluri (NASDAQ:PLUR) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.06). The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.64 million.

Pluri Trading Down 4.9%

Pluri stock opened at $3.19 on Tuesday. Pluri has a 12 month low of $2.82 and a 12 month high of $6.10. The stock has a fifty day simple moving average of $3.38 and a two-hundred day simple moving average of $3.45. The firm has a market cap of $34.30 million, a price-to-earnings ratio of -0.65 and a beta of 0.75.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pluri has an average rating of “Hold” and a consensus target price of $12.00.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC acquired a new position in Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. 16.59% of the stock is owned by institutional investors.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.